Fulgent Genetics on Thursday announced it has launched a PCR test that leverages the U.S. Centers for Disease Control and Prevention’s orthopoxvirus test, which detects non-smallpox related orthopoxviruses, including monkeypox.
Fulgent, a genetic testing company focused on patient care in oncology, infectious and rare diseases, and reproductive health, will begin accepting specimens for testing next week.
"We expect to be able to scale testing capacity for monkeypox rapidly and efficiently, as we did with testing for COVID-19 in early 2020," Brandon Perthuis, chief commercial officer of Fulgent Genetics, said in a statement.